Latest Oncolytic virus Stories
CALGARY, Nov. 18, 2014 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc.
LONDON, Oct. 15. 30, 2014 /PRNewswire/ -- REPORT HIGHLIGHTS The global cancer immunotherapies market reached $30.8 billion in 2012.
SAN DIEGO, Oct. 14, 2014 /PRNewswire/ -- DNAtrix, a clinical-stage oncolytic immunotherapy company, announced that it has completed a $20M Series B equity financing.
SAN DIEGO, Oct. 7, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S.
In the news release, Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S.
CALGARY, Sept. 3, 2014 /PRNewswire/ - Oncolytics Biotech Inc.
First Marketing Authorization Application for an Oncolytic Immunotherapy in the European Union THOUSAND OAKS, Calif., Sept.
CALGARY, Sept. 2, 2014 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc.
SEOUL, South Korea, BUSAN, South Korea and SAN FRANCISCO, July 10, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of
- In medieval musical notation, a sign or neume denoting a shake or trill.